Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous formalin-fixed tumor vaccine
- Development stage
- Unknown
- Lead developer
- Cell-Medicine
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Autologous formalin-fixed tumor vaccine (AFTV) is a personalized cancer immunotherapy consisting of formalin-fixed tumor tissue fragments or cells derived from a patient's own resected malignancy. The formalin fixation process inactivates the tumor cells while preserving the structural integrity of a broad array of unidentified tumor-associated antigens (TAAs). When administered intradermally, typically alongside adjuvants such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2), the vaccine stimulates the patient's immune system to recognize and attack residual tumor cells. Clinical studies have primarily focused on preventing recurrence in glioblastoma multiforme (GBM) and hepatocellular carcinoma (HCC), where it has demonstrated the ability to induce delayed-type hypersensitivity (DTH) responses and glypican-3-specific cytotoxic T lymphocyte activity.
- Other names
- AFTVautologous formalin-fixed tumor cell vaccine
Beyond the preview
Go deeper on autologous formalin-fixed tumor vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous formalin-fixed tumor vaccine.